Blog
RSS FeedPosted by Michael Wonder on 20 Dec 2022
ICER provides update on value based pricing of Paxlovid as an outpatient treatment for COVID-19
20 December 2022 - New data suggests Paxlovid will achieve common thresholds of cost effectiveness if priced between $563-$906 per treatment ...
Posted by Michael Wonder on 10 May 2022
ICER publishes final evidence report and policy recommendations on outpatient treatments for COVID-19
10 May 2022 - Independent appraisal committee votes 11-2 that the evidence is not adequate to demonstrate a net health benefit ...
Posted by Michael Wonder on 28 Mar 2022
ICER publishes evidence report on treatments for COVID-19
28 March 2022 - Current evidence suggests all four drugs under review have prices reasonably aligned with patient benefits. ...
Posted by Michael Wonder on 05 Feb 2022
Price of COVID treatments from Pfizer, Merck, GSK align with patient benefits
3 February 2022 - The prices of drugs used to treat COVID-19 for those at risk of serious illness are ...
Posted by Michael Wonder on 03 Feb 2022
ICER releases draft evidence report on treatments for COVID-19
3 February 2022 - Public comment period now open until 3 March 2022; requests to make oral comment during public ...
Posted by Michael Wonder on 26 Aug 2021
ICER to assess treatments for COVID-19
26 August 2021 - Report will be subject of Midwest CEPAC meeting in April 2022; Draft Scoping Document open to public ...
Posted by Michael Wonder on 11 Mar 2021
The broader societal impacts of COVID-19 and the growing importance of capturing these in health economic analyses
9 March 2021 - The rapid spread of the current COVID-19 pandemic has affected societies worldwide, leading to excess mortality, long ...
Posted by Michael Wonder on 19 Nov 2020
Consideration of value-based pricing for treatments and vaccines is important, even in the COVID-19 pandemic
19 November 2020 - Prices send signals about consumer preferences and thus stimulate producers to make more of what people want. ...
Posted by Michael Wonder on 10 Nov 2020
ICER provides second update to pricing models for remdesivir as a treatment for COVID-19
10 November 2020 - Based on an analysis of four studies evaluating remdesivir’s influence on mortality, ICER has concluded that the ...
Posted by Michael Wonder on 10 Oct 2020
In landmark international program, HTA agencies around the world access ICER's customisable COVID-19 cost-effectiveness model
9 October 2020 - Leveraging ICER’s new cloud-based Interactive Modeler platform, Quebec’s HTA agency has used the COVID-19 model to inform ...
Posted by Michael Wonder on 22 Jul 2020
COVID-19 and ISPOR conferences
22 July 2020 - ISPOR redesigns remaining conferences for 2020. ...
Posted by Michael Wonder on 02 Jul 2020
ICER publishes white paper on alternative policies for drug and vaccine pricing during a pandemic, announces cross-stakeholder discussion series
2 July 2020 - The Institute for Clinical and Economic Review today published a white paper to inform public and policy ...
Posted by Michael Wonder on 24 Jun 2020
ICER provides first update to pricing models for remdesivir as a treatment for COVID-19
24 June 2020 - Updated cost-recovery benchmark price now framed as a range with maximum of $1,600/10 day regimen when incorporating ...
Posted by Michael Wonder on 23 Jun 2020
The case for using novel value elements when assessing COVID-19 vaccines and therapeutics
23 June 2020 - In the span of mere weeks, the novel coronavirus (COVID-19) has upended modern life. Schools and businesses ...
Posted by Michael Wonder on 15 Jun 2020
COVID-19 and remdesivir: rethinking how we measure a drug’s ‘value’
15 June 2020 - As pharmaceutical and biotech companies scramble to identify treatments for COVID-19, a new disease that initially ...